In the future, relevant researches can be carried out to determine the benefits degree of these drugs for HER2-positive advanced breast cancer that failed first-line trastuzumab-based treatments 67, thereby optimizing the second-line treatment strategies for these patients and improving their clinical outcomes. Here, ERBB2 is linked to breast carcinoma.